ReviewBlood research2022
Update on the POEMS syndrome.
Review in Blood research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- POEMS syndrome: A case report.Radiology case reports · 2026Article
- Article
- POEMS syndrome misdiagnosed as liver cirrhosis: a case report.Frontiers in medicine · 2026Article
- A rare coexistence of immunoglobulin light chain amyloidosis and POEMS syndrome manifesting as refractory heart failure: a case report and literature review.Frontiers in immunology · 2026Review
- POEMS Syndrome with Peripheral Neuropathy as the First Presentation: A Case Report.International medical case reports journal · 2026Article
- Concurrent AESOP and POEM syndrome presenting as an indurated plaque: AESOP's paraneoplastic POEM.JAAD case reports · 2025Article
- A case report of Castleman disease variant of POEMS syndrome presenting with prominent polyserositis and renal impairment.Frontiers in medicine · 2025Article
- A case report of an M protein-negative patient with POEMS syndrome associated with renal involvement.BMC nephrology · 2024Article
- A Multicenter Analysis of Clinical Features and Long-Term Outcomes of POEMS Syndrome in Korea.Journal of Korean medical science · 2024Article
- Scleroderma and scleroderma-like syndromes.Frontiers in immunology · 2024Review
- Day -1 CD34+ Cells and Platelet Count Predict the Number of Apheresis in Poor-Mobilizer Patients Rescued by Plerixafor.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
POEMS syndrome is an acronym for polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes. It is a rare paraneoplastic disorder related to plasma cell neoplasm. However, its pathophysiology has not yet been clearly elucidated. The production of pro-inflammatory cytokines is thought to play an important role in the pathogenesis of POEMS syndrome. Vascular endothelial growth factor level reflects disease activity, which is helpful for the diagnosis and evaluation of treatment response. Conventional agents such as corticosteroids and melphalan are effective and safe combination regimens. Autologous hematopoietic stem cell transplantation is another option for high-risk transplant-eligible patients. Radiotherapy is effective in patients with localized lesions. The anti-myeloma agents lenalidomide, thalidomide, and bortezomib have shown good treatment outcomes for POEMS syndrome; however, large-scale studies with long-term follow-up are required. Early identification and active treatment can improve the outcomes of POEMS syndrome patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.